Elanco Animal Health (NYSE:ELAN) Updates FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.030-1.090 for the period, compared to the consensus earnings per share estimate of 1.030. The company issued revenue guidance of $5.0 billion-$5.1 billion, compared to the consensus revenue estimate of $5.0 billion. Elanco Animal Health also updated its Q2 2026 guidance to 0.250-0.285 EPS.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Morgan Stanley raised their price target on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 18th. Leerink Partners lifted their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. lifted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Citigroup lifted their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.20.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN traded down $0.58 during midday trading on Friday, hitting $23.43. The company’s stock had a trading volume of 1,461,438 shares, compared to its average volume of 5,021,964. The stock has a fifty day moving average price of $23.81 and a 200 day moving average price of $23.35. Elanco Animal Health has a one year low of $11.92 and a one year high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $11.65 billion, a price-to-earnings ratio of -47.03, a P/E/G ratio of 3.33 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.37%. Elanco Animal Health’s revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, research analysts forecast that Elanco Animal Health will post 1.04 EPS for the current fiscal year.

Elanco Animal Health News Summary

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 results beat estimates: Elanco reported stronger-than-expected Q1 sales and beat EPS/revenue consensus; revenue growth was roughly mid-teens year-over-year and management set Q2 and FY 2026 guidance. This is the primary catalyst cited by market coverage. Elanco’s Q1 CY2026 Sales Beat Estimates
• Positive Sentiment: Raised guidance and clearer medium‑term targets: Management outlined 5%–7% organic growth and $1.03–$1.09 adjusted EPS for FY2026 and increased its innovation investment target (innovation-led growth cited as a key driver). That formal guidance lift improved the outlook and was highlighted in analyst commentary. Elanco outlines guidance and innovation target
• Positive Sentiment: Analyst upgrades / higher price targets: JPMorgan and Citigroup raised their price targets and maintained overweight/buy stances (new targets roughly $30–$31), reinforcing the rally by signaling more upside vs. prior levels. JPMorgan raises target Citigroup raises target
• Positive Sentiment: Product approvals / emergency use authorizations: Recent approvals for new products (Negasunt Powder and Tanidil) were highlighted as added product momentum that supports growth and margin improvement over time. Product approvals coverage
• Neutral Sentiment: Earnings call materials available: The full Q1 earnings call transcript and the investor presentation were posted, giving investors detailed line‑by‑line guidance, product pipeline commentary and segment results to dig into execution vs. targets. (Useful for modeling but not new headline news.) Earnings call transcript
• Neutral Sentiment: CEO interview / investor outreach: A Bloomberg podcast featuring CEO Jeff Simmons provided additional color on strategy and execution — helpful context but not a direct driver compared with the beats/guidance and analyst moves. Bloomberg CEO interview

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its stake in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at $41,000. Geneos Wealth Management Inc. boosted its stake in shares of Elanco Animal Health by 53.7% in the 2nd quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after purchasing an additional 2,080 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Elanco Animal Health by 26.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after purchasing an additional 1,332 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Elanco Animal Health by 31.9% in the 4th quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock valued at $127,000 after purchasing an additional 1,358 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.